Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Stomach Neoplasms 2Penile Neoplasms 2Oropharyngeal Neoplasms 2Melanoma 2Anus Neoplasms 2Neoplasm Metastasis 1Lung Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Gemcitabine 112Cisplatin 76Oxaliplatin 44pembrolizumab 34Fluorouracil 32Capecitabine 30durvalumab 27Leucovorin 26lenvatinib 23Magnetic Resonance Spectroscopy 15Irinotecan 14Nivolumab 12Biopsy 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11Drug Therapy 11pemigatinib 10apatinib 10Taxes 10Floxuridine 10130-nm albumin-bound paclitaxel 10Radiotherapy 9Bevacizumab 9Platinum 8Folfox protocol 8Carboplatin 81,2-diaminocyclohexaneplatinum II citrate 8tremelimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cholangiocarcinoma × Adoptive Transfer × Clear all
NCT02757391 2020-10-30

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

M.D. Anderson Cancer Center

Phase 1 Terminated
1 enrolled
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡